Peregrine Pharmaceuticals Provides Update on Phase III SUNRISE Trial of Bavituximab
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Roth Capital Downgrades Peregrine Pharmaceuticals (PPHM) to Neutral
February 26, 2016 7:21 AM ESTRoth Capital downgraded Peregrine Pharmaceuticals (NASDAQ: PPHM) from Buy to Neutral.
For an analyst ratings summary and ratings history on Peregrine Pharmaceuticals click here. For more ratings news on Peregrine Pharmaceuticals click here.
Shares of Peregrine Pharmaceuticals closed at $1.07 yesterday.
... More